Patient Guide: Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

  • Get matched to the right study location for you
  • Connect directly with study coordinators at 180 participating sites
  • Understand eligibility with our simplified screening tool
  • Free service - we're here to help you access clinical research
Trial ID: NCTNCT05609968
Status: ACTIVE_NOT_RECRUITING
Condition: Carcinoma, Non-Small-Cell Lung
Phase: PHASE3

Find a Study Location Near You

This study is available at 180 research sites. We'll help you connect with the location that's right for you.

Participating sites include:
  • Mobile, Alabama
  • Oceanside, California
  • Clermont, Florida
  • • And 177 more locations - let us help you find the closest one

Loading interactive enrollment tools...

The full interactive experience will load momentarily